269 active trials 139 recruiting 30 Phase 3 153 sponsors 54 changes in 30 days
30 trials changed in the last 30 days: 2 stopped, 11 with notable changes, 17 with minor changes only.
Trial terminated
Sponsor's reason: Loss of further funding
Also in this update: Primary completion date changed from estimate of Mar 31, 2027 to Aug 28, 2026; Final enrollment: 21 participants (planned 42)
Washington University School of MedicineEarly Phase 1 NCT06636175 Registry history of NCT06636175 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment suspended
Sponsor's reason: Insufficient funding
Fred Hutchinson Cancer CenterPhase 1/2 NCT07098364 Registry history of NCT07098364 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Apr 2027 to Sep 2028
Eli Lilly and CompanyPhase 1 NCT07226843 Registry history of NCT07226843 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Mar 23, 2027 to Aug 24, 2029
City of Hope Medical CenterPhase 2 NCT05672251 Registry history of NCT05672251 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Jan 1, 2027 to Aug 1, 2027
Also in this update: Completion pushed from Jan 1, 2028 to Aug 1, 2028
Marcela V. Maus, M.D.,Ph.D.Phase 1 NCT06026319 Registry history of NCT06026319 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Mar 9, 2026 to Apr 28, 2029
Also in this update: Completion pushed from May 11, 2026 to Sep 18, 2029
Shanghai Exuma Biotechnology Ltd.Phase 1 NCT06830031 Registry history of NCT06830031 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Aug 1, 2026 to Aug 1, 2027
Also in this update: Interventions modified; Completion pushed from Aug 1, 2027 to Aug 1, 2028
Marcela V. Maus, M.D.,Ph.D.Phase 2 NCT06550141 Registry history of NCT06550141 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Sep 1, 2026 to Jun 1, 2027
National Cancer Institute (NCI)Phase 1 NCT05627245 Registry history of NCT05627245 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Sep 2, 2026 to Aug 11, 2027
City of Hope Medical CenterPhase 1 NCT02153580 Registry history of NCT02153580 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Mar 1, 2028 to Mar 1, 2030
Also in this update: Primary endpoint(s) modified; Enrollment increased: 45 → 71 participants
Reid Merryman, MDPhase 2 NCT06563596 Registry history of NCT06563596 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Umoja BiopharmaPhase 1/2 NCT07735533 Registry history of NCT07735533 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment reopened
Also in this update: Enrollment increased: 60 → 80 participants
M.D. Anderson Cancer CenterPhase 2 NCT04404088 Registry history of NCT04404088 on ClinicalTrials.gov (opens the registry)
Updated
Results posted: Oct 7, 2026
H. Lee Moffitt Cancer Center and Research InstitutePhase 2 NCT04745559 Registry history of NCT04745559 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Pell Bio-Med Technology Co., Ltd.Phase 1/2 NCT05326243 Registry history of NCT05326243 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Final enrollment: 539 participants (planned 700)
Janssen Research & Development, LLCPhase 3 NCT01804686 Registry history of NCT01804686 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Nov 2026 to Mar 2027
Also in this update: Completion pushed from Nov 2029 to Mar 2030
BeOne MedicinesPhase 1/2 NCT05006716 Registry history of NCT05006716 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Final enrollment: 40 participants (planned 50)
Gustave Roussy, Cancer Campus, Grand ParisNot applicable NCT06813573 Registry history of NCT06813573 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 116 → 111 locations
The Lymphoma Academic Research OrganisationPhase 3 NCT06284122 Registry history of NCT06284122 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Study completion date changed from estimate of Dec 31, 2026 to Aug 28, 2026
David Bond, MDPhase 1/2 NCT03015896 Registry history of NCT03015896 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 24 → 20 locations
Fondazione Italiana Linfomi - ETSPhase 2 NCT06492837 Registry history of NCT06492837 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Fred Hutchinson Cancer CenterPhase 1 NCT05359211 Registry history of NCT05359211 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Mar 3, 2027 to Jun 10, 2027
Also in this update: Completion pushed from Mar 3, 2027 to Sep 9, 2028
Mayo ClinicPhase 2 NCT06834373 Registry history of NCT06834373 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 26 → 32 locations
Merck Sharp & Dohme LLCPhase 2/3 NCT07634471 Registry history of NCT07634471 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 41 → 46 locations
Merck Sharp & Dohme LLCPhase 1/2 NCT07519772 Registry history of NCT07519772 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 10 → 13 locations
Tempus AINot specified NCT07154823 Registry history of NCT07154823 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 228 → 235 locations
AstraZenecaPhase 3 NCT06549595 Registry history of NCT06549595 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 276 → 282 locations
National Cancer Institute (NCI)Phase 3 NCT06337318 Registry history of NCT06337318 on ClinicalTrials.gov (opens the registry)
Changed
Interventions modified
PfizerPhase 1 NCT03460977 Registry history of NCT03460977 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion date changed from estimate of Aug 2026 to May 27, 2026
Reid Merryman, MDPhase 2 NCT05783596 Registry history of NCT05783596 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Aug 15, 2026 to Apr 15, 2027
Also in this update: Primary completion date changed from estimate of Aug 15, 2026 to Apr 22, 2020
Beth ChristianPhase 1 NCT02992522 Registry history of NCT02992522 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-08-26 | NCT07788118 A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell… | Second Affiliated Hospital, Zhejiang University, School of Medicine new | Phase 1/2 |
| 2026-08-06 | NCT07750886 Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin… | Natera, Inc. new | |
| 2026-07-30 | NCT07735533 A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies | Umoja Biopharma new | Phase 1/2 |
| 2026-07-30 | NCT07736950 A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without… | Australasian Leukaemia and Lymphoma Group new | Phase 3 |
| 2026-07-22 | NCT07719855 A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of… | Ruijin Hospital new | Phase 3 |
| Early Phase 1 | 2 | |
| Phase 1 | 62 | |
| Phase 1/2 | 39 | |
| Phase 2 | 90 | |
| Phase 2/3 | 3 | |
| Phase 3 | 27 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT06337318 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden… | National Cancer Institute (NCI) | Recruiting | 2026-10-09 |
| NCT06149286 | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better… | Regeneron Pharmaceuticals | Recruiting | 2026-10-07 |
| NCT06091254 | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works… | Regeneron Pharmaceuticals | Recruiting | 2026-10-06 |
| NCT06549595 | A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular… | AstraZeneca | Recruiting | 2026-09-21 |
| NCT05929222 | Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage… | Fondazione Italiana Linfomi - ETS | Recruiting | 2026-09-08 |
| NCT07562022 | A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in… | Sinocelltech Ltd. | Recruiting | 2026-08-13 |
| NCT06911502 | A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab… | Celgene | Recruiting | 2026-05-20 |
| NCT05045664 | Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody | Heidelberg University | Recruiting | 2026-04-28 |
| NCT07029217 | A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas | Memorial Sloan Kettering Cancer Center | Recruiting | 2026-02-17 |
| NCT04834024 | MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab… | Beijing Mabworks Biotech Co., Ltd. | Recruiting | 2024-11-20 |
| NCT04712097 | A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With… | Hoffmann-La Roche | Active, Not Recruiting | 2026-10-08 |
| NCT04224493 | A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of… | Epizyme, Inc. | Active, Not Recruiting | 2026-10-05 |
| NCT01804686 | A Long-term Extension Study of PCI-32765 (Ibrutinib) | Janssen Research & Development, LLC | Active, Not Recruiting | 2026-10-01 |
| NCT07736950 | A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without… | Australasian Leukaemia and Lymphoma Group | Not Yet Recruiting | 2026-09-30 |
| NCT05100862 | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants… | BeOne Medicines | Active, Not Recruiting | 2026-09-28 |
| NCT06284122 | Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy… | The Lymphoma Academic Research Organisation | Active, Not Recruiting | 2026-09-25 |
| NCT04680052 | A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and… | Incyte Corporation | Active, Not Recruiting | 2026-09-04 |
| NCT02390869 | Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for… | Fondazione Italiana Linfomi - ETS | Active, Not Recruiting | 2026-08-19 |
| NCT06191744 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral… | Genmab | Active, Not Recruiting | 2026-08-04 |
| NCT07719855 | A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of… | Ruijin Hospital | Not Yet Recruiting | 2026-07-22 |
| NCT05409066 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral… | Genmab | Active, Not Recruiting | 2026-07-08 |
| NCT05058404 | Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment… | Fondazione Italiana Linfomi - ETS | Active, Not Recruiting | 2026-06-26 |
| NCT05888493 | A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult… | Novartis Pharmaceuticals | Active, Not Recruiting | 2026-04-17 |
| NCT06097364 | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated… | Regeneron Pharmaceuticals | Active, Not Recruiting | 2026-02-06 |
| NCT07355283 | IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in… | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not Yet Recruiting | 2026-01-27 |
City of Hope Medical Center (13) · National Cancer Institute (NCI) (11) · M.D. Anderson Cancer Center (9) · Fondazione Italiana Linfomi - ETS (7) · University of Washington (7) · Genmab (5) · Mayo Clinic (5) · Sun Yat-sen University (5) · Institute of Hematology & Blood Diseases Hospital, China (4) · Memorial Sloan Kettering Cancer Center (4)